EUVIMEDEUVIMED entdecken
Crossref

Curcumol Ameliorates Cisplatin-induced Nephrotoxicity by Targeting TAK1 and Inhibiting MAPK and NF-κB Pathways

Xuejin Jin, Miao Yuan, Lingkun Wang, Huiyan Zha, Zhiwei Zheng, Zheng Xu, Jing Shi, Guang Liang, Qian Zhou

Phytomedicine · 2025

DOI: 10.1016/j.phymed.2025.156752 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Phytomedicine, 2025. Verfasst von Xuejin Jin und 8 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmaceutical Sciences, School of Food Science and Engineering, Hangzhou Medical College, Hangzhou, Zhejiang 311399, China. Hauptthemen laut MEDLINE: Cisplatin, Acute Kidney Injury, NF-kappa B, MAP Kinase Kinase Kinases. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 30 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Although cisplatin (Cis) is a foundational chemotherapeutic agent, its dose-limiting nephrotoxicity lacks clinically effective drugs. Curcumol (CUR), a bioactive sesquiterpenoid derived from Curcuma zedoariae rhizome, exhibits multi-organ protective effects. However, its therapeutic potential and molecular targets in Cis-provoked acute kidney injury (AKI) remain unexplored. PURPOSE: This study systematically investigated the nephroprotection and underlying mechanism of CUR in Cis-induced nephrotoxicity. METHODS: C57BL/6 mice received intraperitoneal administration of 20 mg/kg Cis to induce AKI. Dual-concentration CUR (40/80 mg/kg) was administered pre- and post-treatment in Cis-challenged mice, with longitudinal monitoring of renal function. Human tubular epithelial cells (HK-2 cells) were used to evaluate CUR's nephroprotection in vitro. RNA-sequencing transcriptomics identified pathway-level mechanisms, while structure-based molecular docking (MOD) prioritized target proteins. RESULTS: CUR exhibited dose-responsive nephroprotection, reducing apoptosis, oxidative stress, and inflammation more effectively than N-acetylcysteine in pre- and post-Cis treatment regimens. Mechanistically, we revealed that nephroprotection of CUR primarily involves suppression of phosphorylation-mediated MAPK/NF-κB pathway activation, thereby mitigating the inflammatory response. Notably, MOD and Cellular thermal shift assay (CETSA) data suggested a direct interaction between CUR and TAK1. Functional validation experiments demonstrated that TAK1 silencing attenuated cisplatin-induced tubular cell injury, and TAK1 activity was essential for CUR's protective effects. CONCLUSION: CUR ameliorated Cis-triggered AKI by targeting TAK1 and inhibiting MAPK and NF-κB pathways. These findings suggest that CUR may serve as a promising adjuvant to overcome the primary limitation of Cis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CisplatinAcute Kidney InjuryNF-kappa BMAP Kinase Kinase KinasesSesquiterpenesAnimalsMice, Inbred C57BLHumansMiceMaleApoptosisCell LineMolecular Docking SimulationOxidative StressSignal TransductionMAP Kinase Signaling SystemCurcumaAntineoplastic AgentsMAP Kinase Kinase Kinase 7

Stichwörter der Autor:innen

Acute kidney injuryCisplatinCurcumolMAPKNF-ΚbTAK1

Substanzen

CisplatinNF-kappa BMAP Kinase Kinase KinasesSesquiterpenesAntineoplastic AgentsMAP Kinase Kinase Kinase 7curcumol

Autor:innen und Institutionen

  • School of Pharmaceutical Sciences, School of Food Science and Engineering, Hangzhou Medical College, Hangzhou, Zhejiang 311399, China.
  • Zhejiang Province Key Laboratory of Anti-Cancer Drug Research, Center for Drug Safety Evaluation and Research, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, China.
  • Zhejiang Provincial People's Hospital, Affiliated People's Hospital, Hangzhou Medical College, Hangzhou 310014, China.
  • School of Pharmaceutical Sciences, School of Food Science and Engineering, Hangzhou Medical College, Hangzhou, Zhejiang 311399, China. Electronic address: qianz1220@hmc.edu.cn.

Zitieren

APA

Jin, X., Yuan, M., Wang, L., Zha, H., Zheng, Z., Xu, Z., Shi, J., Liang, G., & Zhou, Q. (2025). Curcumol Ameliorates Cisplatin-induced Nephrotoxicity by Targeting TAK1 and Inhibiting MAPK and NF-κB Pathways. Phytomedicine. https://doi.org/10.1016/j.phymed.2025.156752

Vancouver

Jin X, Yuan M, Wang L, Zha H, Zheng Z, Xu Z, et al. Curcumol Ameliorates Cisplatin-induced Nephrotoxicity by Targeting TAK1 and Inhibiting MAPK and NF-κB Pathways. Phytomedicine. 2025. doi:10.1016/j.phymed.2025.156752

BibTeX
@article{Jin2025,
  author = {Jin, Xuejin and Yuan, Miao and Wang, Lingkun and Zha, Huiyan and Zheng, Zhiwei and Xu, Zheng and Shi, Jing and Liang, Guang and Zhou, Qian},
  title = {Curcumol Ameliorates Cisplatin-induced Nephrotoxicity by Targeting TAK1 and Inhibiting MAPK and NF-κB Pathways},
  journal = {Phytomedicine},
  year = {2025},
  doi = {10.1016/j.phymed.2025.156752}
}
Kostenlos starten →